n.— «Q: Will large drugmakers rely even more heavily on buying the rights to discoveries made by others, a practice called inlicensing? A: Inlicensing has been an important source of new medicines for Pfizer, providing about 40 percent of the company’s drug development pipeline. I see us continuing to partner with small companies and academic institutions.» —“Making medicine getting tougher” News & Observer (Raleigh, North Carolina) Sept. 10, 2008. (source: Double-Tongued Dictionary)

Tagged with →  

This site uses Akismet to reduce spam. Learn how your comment data is processed.